Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients

The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients.

The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis.

To investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis. Patients with liver cirrhosis were randomly separated into two groups. Umbilical cord MSCs were infused to patients using interventional method via hepatic artery for One group. After the catheter placed at proper hepatic artery was confirmed by angiography, umbilical cord MSCs were infused slowly for 15-20minutes. The control group accepted conserved therapy.

Inclusion Criteria:

• Aged 18~70 years.
• Liver cirrhosis
• written consent

Exclusion Criteria:

• The end-stage of liver cirrhosis.
• Severe problems in other vital organs(e.g.the heart,renal or lungs).
• Hepatocellular carcinoma or other malignancies
• Pregnancy
• sepsis
• Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)
• Cardiac, renal or respiratory failure
• Active thrombosis of the portal or hepatic veins